Inovio Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Inovio Pharmaceuticals CEO'su Jacqueline Shea, May2022 tarihinde atandı, in görev süresi 2.5 yıldır. in toplam yıllık tazminatı $ 2.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 30.8% maaş ve 69.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.13% ine doğrudan sahiptir ve bu hisseler $ 177.66K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 5.8 yıldır.
Anahtar bilgiler
Jacqueline Shea
İcra Kurulu Başkanı
US$2.4m
Toplam tazminat
| CEO maaş yüzdesi | 30.8% |
| CEO görev süresi | 2.5yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 3.4yrs |
| Yönetim Kurulu ortalama görev süresi | 5.8yrs |
Son yönetim güncellemeleri
Recent updates
Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation
Aug 11
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates
May 15Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates
May 13Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?
Oct 23Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug
Oct 13Inovio Pharmaceuticals: Long On Promise, Short On Results
Sep 27Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M
Aug 09Inovio: After All These Years
Jul 19Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022
Apr 15Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?
Mar 21Inovio Undervalued On Potential 2022 Catalyst
Jan 26Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Dec 31Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side
Nov 18Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt
Sep 24Inovio: Simply Cannot Be Ignored
Sep 03CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$122m |
| Mar 31 2024 | n/a | n/a | -US$125m |
| Dec 31 2023 | US$2m | US$751k | -US$135m |
| Sep 30 2023 | n/a | n/a | -US$165m |
| Jun 30 2023 | n/a | n/a | -US$168m |
| Mar 31 2023 | n/a | n/a | -US$241m |
| Dec 31 2022 | US$4m | US$730k | -US$280m |
| Sep 30 2022 | n/a | n/a | -US$332m |
| Jun 30 2022 | n/a | n/a | -US$355m |
| Mar 31 2022 | n/a | n/a | -US$328m |
| Dec 31 2021 | US$2m | US$468k | -US$304m |
| Sep 30 2021 | n/a | n/a | -US$221m |
| Jun 30 2021 | n/a | n/a | -US$142m |
| Mar 31 2021 | n/a | n/a | -US$188m |
| Dec 31 2020 | US$2m | US$431k | -US$166m |
| Sep 30 2020 | n/a | n/a | -US$180m |
| Jun 30 2020 | n/a | n/a | -US$222m |
| Mar 31 2020 | n/a | n/a | -US$123m |
| Dec 31 2019 | US$1m | US$335k | -US$119m |
Tazminat ve Piyasa: Jacqueline 'nin toplam tazminatı ($USD 2.44M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 654.40K ).
Tazminat ve Kazançlar: Jacqueline 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Jacqueline Shea (58 yo)
2.5yrs
Görev süresi
US$2,438,908
Tazminat
Dr. Jacqueline E. Shea, Ph D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Opera...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 2.5yrs | US$2.44m | 0.13% $ 177.7k | |
| Chief Financial Officer | 22.4yrs | US$1.16m | 0.095% $ 130.6k | |
| Chief Scientific Officer & Chairman of the Scientific Advisory Board | 5.7yrs | US$1.14m | 0.094% $ 128.5k | |
| Manager of Investor Relations | no data | Veri yok | Veri yok | |
| General Counsel & Chief Compliance Officer | 3yrs | Veri yok | Veri yok | |
| Senior Vice President of Quality Assurance | no data | Veri yok | Veri yok | |
| Senior Vice President of Clinical Development | 4.1yrs | Veri yok | Veri yok | |
| Senior Vice President of Biological Manufacturing & Clinical Supply Management | 4.1yrs | Veri yok | Veri yok | |
| Senior Vice President of Business Development | 3.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Early-Stage Clinical Development | less than a year | Veri yok | Veri yok | |
| Chief Medical Officer | 2.4yrs | Veri yok | 0.032% $ 43.4k | |
| Senior Vice President of Regulatory Affairs | 1.7yrs | Veri yok | Veri yok |
3.4yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim: INO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 2.5yrs | US$2.44m | 0.13% $ 177.7k | |
| Chief Scientific Officer & Chairman of the Scientific Advisory Board | less than a year | US$1.14m | 0.094% $ 128.5k | |
| Independent Director | 6.9yrs | US$123.69k | 0.032% $ 44.1k | |
| Independent Director | 5.8yrs | US$118.69k | 0.025% $ 34.6k | |
| Independent Director | 4.8yrs | US$119.31k | 0.027% $ 37.2k | |
| Independent Chairman of Board of Directors | 20.9yrs | US$151.19k | 0.039% $ 52.9k | |
| Member of the Scientific Advisory Board & Director | 8.7yrs | US$201.79k | 0.32% $ 435.6k | |
| Member of Scientific Advisory Board | 15.4yrs | Veri yok | Veri yok | |
| Independent Director | 5.7yrs | US$126.94k | 0.030% $ 40.7k | |
| Independent Director | 3.5yrs | US$108.69k | 0.026% $ 35.6k | |
| Member of Scientific Advisory Board | 6yrs | Veri yok | Veri yok |
5.8yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: INO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.8 yıldır).